Beigene Ltd (NASDAQ:BGNE) Director Donald W. Glazer sold 41,463 shares of the business’s stock in a transaction dated Wednesday, September 28th. The stock was sold at an average price of $30.66, for a total transaction of $1,271,255.58. Following the completion of the transaction, the director now directly owns 4,881,997 shares in the company, valued at $149,682,028.02. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Shares of Beigene Ltd (NASDAQ:BGNE) opened at 30.81 on Friday. The company has a 50-day moving average price of $29.97 and a 200-day moving average price of $29.07. Beigene Ltd has a 52 week low of $22.51 and a 52 week high of $35.60. The company’s market capitalization is $1.01 billion.
Beigene (NASDAQ:BGNE) last issued its earnings results on Wednesday, August 10th. The company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by $0.05. The business earned $0.40 million during the quarter, compared to analyst estimates of $2.08 million. Beigene’s revenue was down 71.4% compared to the same quarter last year. Analysts predict that Beigene Ltd will post ($3.38) earnings per share for the current year.
Several large investors have recently modified their holdings of the company. FMR LLC boosted its stake in shares of Beigene by 34.0% in the second quarter. FMR LLC now owns 2,300,337 shares of the company’s stock valued at $68,550,000 after buying an additional 583,277 shares in the last quarter. Hillhouse Capital Management Ltd. purchased a new stake in shares of Beigene during the first quarter valued at $20,517,000. Boxer Capital LLC boosted its stake in shares of Beigene by 18.4% in the second quarter. Boxer Capital LLC now owns 493,630 shares of the company’s stock valued at $14,710,000 after buying an additional 76,751 shares in the last quarter. Temasek Holdings Private Ltd purchased a new stake in shares of Beigene during the first quarter valued at $11,138,000. Finally, VHCP Management II LLC purchased a new stake in shares of Beigene during the first quarter valued at $3,488,000.
A number of brokerages recently weighed in on BGNE. Zacks Investment Research raised shares of Beigene from a “sell” rating to a “hold” rating in a report on Monday, September 12th. Maxim Group began coverage on shares of Beigene in a report on Wednesday, September 21st. They issued a “buy” rating and a $41.00 price target on the stock. Finally, Cowen and Company reissued a “buy” rating on shares of Beigene in a report on Monday, June 6th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $40.00.
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.
Receive News & Ratings for Beigene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.